SRNE•benzinga•
Levena Biopharma, A Sorrento Company, Announces Clinical Data For Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 3, 2022 by benzinga